| HRA006345
(Controlled Access)
|
The objective is to assess the efficacy and safety of precision induction therapies in patients with unresectable stage III NSCLC selected based on tumor PD-L1 expression. Patients were stratified into groups receiving Sintilimab monotherapy, Sintilimab plus IBI305, or Sintilimab combined with chemotherapy. Multi-disciplinary team (MDT) to discuss whether surgery was performed 3-4 weeks after last dose of therapy. Surgery was performed 4-6 weeks after last dose of induction therapy. RNA-seq and WES were performed at baseline, and the tumor samples were also collected for RNA-seq after surgery. Based on bioinformatics analysis, we want to find better biomarker to stratified patients and explore optimized regimens for unresectable stage III NSCLC. |
